Trasplante hepático: inmunosupresión personalizada en pacientes con hepatitis C y carcinoma hepatocelular

García-Retortillo, 2002, Hepatitis C virus kinetics during and immediately after liver transplantation, Hepatology, 35, 680, 10.1053/jhep.2002.31773 Samuel, 2006, Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006), J Hepatol, 45, 127, 10.1016/j.jhep.2006.05.001 Gane, 2003, The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients, Liver Transpl, 9, S28, 10.1053/jlts.2003.50248 Berenguer, 2005, What determines the natural history of recurrent hepatitis C after liver transplantation, J Hepatol, 42, 448, 10.1016/j.jhep.2005.01.011 Forman, 2002, The association between hepatitis C infection and survival after orthotopic liver transplantation, Gastroenterology, 122, 889, 10.1053/gast.2002.32418 Neumann, 2004, Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up, Transplantation, 77, 226, 10.1097/01.TP.0000101738.27552.9D Gedaly, 2008, Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey, Transpl Int, 21, 867, 10.1111/j.1432-2277.2008.00699.x Berenguer, 2006, Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression, J Hepatol, 44, 717, 10.1016/j.jhep.2006.01.005 O’Leary, 2011, Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation, Proc (Bayl Univ Med Cent), 24, 187, 10.1080/08998280.2011.11928712 Irish, 2011, Cyclosporine versus Tacrolimus Treated Liver Transplant Recipients with Chronic Hepatitis C: Outcomes Analysis of the UNOS/OPTN Database, Am J Transplant, 1676-85 Berenguer, 2011, Viral hepatitis: Ciclosporin versus tacrolimus for HCV transplant recipients, Nat Rev Gastroenterol Hepatol, 8, 422, 10.1038/nrgastro.2011.124 Martin, 2004, Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial, Liver Transpl, 10, 1258, 10.1002/lt.20222 Levy, 2006, 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus, Liver Transpl, 12, 1464, 10.1002/lt.20802 O’Grady, 2007, Randomized controlled retrial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years, Am J Transplant, 7, 137, 10.1111/j.1600-6143.2006.01576.x Berenguer, 2006, Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients, Liver Transpl, 12, 762, 10.1002/lt.20655 Berenguer, 2010, Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus positive recipients, Transplantation, 90, 1204, 10.1097/TP.0b013e3181fa93fa Berenguer, 2007, Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis, Liver Transpl, 13, 21, 10.1002/lt.21035 Haym MB, Torra RC, Acevedo JM, Cañizares RB, Morencos FC, Fuste LC, et al. III Reunión de consenso de la Sociedad Española de Trasplante Hepático (SETH). Hepatitis C, trasplante hepático de donante vivo, calidad de los injertos hepáticos y calidad de los programas de trasplante hepático. Cir Esp. 2011;89:487-504. Nakagawa, 2005, Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins, Gastroenterology, 129, 1031, 10.1053/j.gastro.2005.06.031 Firpi, 2010, The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study, Dig Dis Sci, 55, 196, 10.1007/s10620-009-0981-3 Gane, 1996, Long-term outcome of hepatitis C infection after liver transplantation, N Engl J Med, 334, 815, 10.1056/NEJM199603283341302 Berenguer, 1998, Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection, J Hepatol, 28, 756, 10.1016/S0168-8278(98)80224-9 Lake, 2003, The role of immunosuppression in recurrence of hepatitis C, Liver Transpl, 9, S63, 10.1053/jlts.2003.50264 Samonakis, 2005, Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation, Liver Transpl, 11, 384, 10.1002/lt.20344 Brillanti, 2002, Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation, Liver Transpl, 8, 884, 10.1053/jlts.2002.34640 Vivarelli, 2007, Influence of steroids on HCV recurrence after liver transplantation: A prospective study, J Hepatol, 47, 793, 10.1016/j.jhep.2007.07.023 Margarit, 2005, A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C, Transpl Int, 18, 1336, 10.1111/j.1432-2277.2005.00217.x Llado, 2008, Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study, Liver Transpl, 14, 1752, 10.1002/lt.21629 Klintmalm, 2011, A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C, Liver Transpl, 17, 1394, 10.1002/lt.22417 Segev, 2008, Steroid avoidance in liver transplantation:meta-analysis and meta-regression of randomized trials, Liver Transpl, 14, 512, 10.1002/lt.21396 Sgourakis, 2009, Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes, Transpl Int, 22, 892, 10.1111/j.1432-2277.2009.00893.x Zekry, 2004, A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection, Liver Transpl, 10, 52, 10.1002/lt.20000 Jain, 2002, A prospective randomized trial of Mycophenolate Mofetil in liver transplant recipients with hepatitis C, Liver Transpl, 8, 40, 10.1053/jlts.2002.29763 Manousou, 2009, Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy, Liver Transpl, 15, 1783, 10.1002/lt.21907 Germani, 2009, Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil, Am J Transplant, 9, 1725, 10.1111/j.1600-6143.2009.02705.x McCaughan, 2004, Mechanisms of HCV reinfection and allograft damage after liver transplantation, J Hepatol, 40, 368, 10.1016/j.jhep.2004.01.014 Neumann, 2004, Fibrosis progression after liver transplantation in patients with recurrent hepatitis C, J Hepatol, 41, 830, 10.1016/j.jhep.2004.06.029 Calmus, 2002, Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients, Liver Transpl, 8, 123, 10.1053/jlts.2002.30882 Neuhaus, 2002, Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial, Liver Transpl, 8, 132, 10.1053/jlts.2002.30302 Sehgal, 1998, Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action of immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression, Clin Biochem, 31, 335, 10.1016/S0009-9120(98)00045-9 Akselband, 1991, Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts, Transplant Proc, 2833 Zhu, 1999, Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis, Gastroenterology, 117, 1198, 10.1016/S0016-5085(99)70406-3 Neef, 2006, Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis, J Hepatol, 45, 786, 10.1016/j.jhep.2006.07.030 Patsenker, 2011, Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis, J Hepatol, 55, 388, 10.1016/j.jhep.2010.10.044 Wagner, 2010, Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates, Int Immunopharmacol, 10, 990, 10.1016/j.intimp.2010.05.006 McKenna, 2011, Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression, Am J Transplant, 11, 2379, 10.1111/j.1600-6143.2011.03767.x Asthana, 2011, The impact of sirolimus on hepatitis C recurrence after liver transplantation, Can J Gastroenterol, 25, 28, 10.1155/2011/201019 Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104 Davis, 2011, Treatment of recurrent hepatocellular carcinoma after liver transplantation, Liver Transpl, 17, S162, 10.1002/lt.22361 Hojo, 1999, Cyclosporine induces cancer progression by a cell-autonomous mechanism, Nature, 397, 530, 10.1038/17401 Herman, 2001, Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients, J Lab Clin Med, 137, 14, 10.1067/mlc.2001.111469 Guba, 2002, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat Med, 8, 128, 10.1038/nm0202-128 Schumacher, 2002, Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth, Transplant Proc, 34, 1392, 10.1016/S0041-1345(02)02899-3 Dantal, 1998, Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regyhimens, Lancet, 351, 623, 10.1016/S0140-6736(97)08496-1 Vivarelli, 2002, Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression, Transplantation, 74, 1746, 10.1097/00007890-200212270-00017 Vivarelli, 2008, Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence, Ann Surg, 248, 857, 10.1097/SLA.0b013e3181896278 Yokoyama, 1991, Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation, Cancer, 68, 2095, 10.1002/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y Shirouzu, 2010, Rapamycin inhibits proliferation and migration of hepatoma cells in vitro, J Surg Res, 159, 705, 10.1016/j.jss.2008.07.035 Semela, 2007, Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma, J Hepatol, 46, 840, 10.1016/j.jhep.2006.11.021 Guba, 2005, Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF, Blood, 105, 4463, 10.1182/blood-2004-09-3540 Schlitt, 2011, Hepatocellular carcinoma: agents and concepts for reventing recurrence after curative treatment, Liver Transpl, S10, 10.1002/lt.22411 Toso, 2007, De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects, Transplantation, 83, 1162, 10.1097/01.tp.0000262607.95372.e0 Zimmerman, 2008, Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma, Liver Transpl, 14, 633, 10.1002/lt.21420 Zhou, 2006, Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience, World J Gastroenterol, 12, 3114, 10.3748/wjg.v12.i19.3114 Chinnakotla, 2009, Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation, Liver Transpl, 15, 1834, 10.1002/lt.21953 Vivarelli, 2010, Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma, Transplantation, 89, 227, 10.1097/TP.0b013e3181c3c540 Toso, 2010, Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma, Hepatology, 51, 1237, 10.1002/hep.23437 Liang, 2012, Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis, Liver Transpl, 18, 62, 10.1002/lt.22441 Toso, 2007, De novo sirolimus based mmunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects, Transplantation, 83, 1162, 10.1097/01.tp.0000262607.95372.e0 Schnitzbauer, 2010, A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma, BMC Cancer, 10, 190, 10.1186/1471-2407-10-190 Gomez-Martin, 2012, Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation, Liver Transpl, 18, 45, 10.1002/lt.22434